Roche Exits Semiconductor, Nanopore Sequencing; Cuts 60 Positions at 454 as It Builds New NGS Unit | GenomeWeb

Roche is shutting down its research and development efforts in semiconductor sequencing and nanopore sequencing and is consolidating its 454 and NimbleGen products into a new sequencing unit that will cover both life science and clinical diagnostic applications.

The changes are part of the company's decision, announced today, to dissolve Roche Applied Science, the life science unit of its Diagnostics division, by the end of this year and to integrate Applied Science's products with other units.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.